MP27-08 CLINICAL CORRELATES AND ECONOMIC CONSEQUENCES OF EMPLOYER BENEFIT EXCLUSION FOR PENILE PROSTHESIS IMPLANTATION FOR ERECTILE DYSFUNCTION

Abstract

You have accessJournal of UrologySexual Function/Dysfunction: Evaluation I (MP27)1 Sep 2021MP27-08 CLINICAL CORRELATES AND ECONOMIC CONSEQUENCES OF EMPLOYER BENEFIT EXCLUSION FOR PENILE PROSTHESIS IMPLANTATION FOR ERECTILE DYSFUNCTION Sirikan Rojanasarot, Samir Bhattacharyya, and Arthur L. Burnett Sirikan RojanasarotSirikan Rojanasarot More articles by this author , Samir BhattacharyyaSamir Bhattacharyya More articles by this author , and Arthur L. BurnettArthur L. Burnett More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002024.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Employed men with erectile dysfunction (ED) covered by employer-sponsored health insurance (ESHI) often have limited access to penile prosthesis implantation (PPI). This study quantified the clinical correlates and economic consequences of the benefit exclusion by examining the prevalence and comorbid correlations of ED among men with ESHI; the population size of ED men affected by the issue; and the economic impact of work productivity loss due to benefit exclusion for PPI. METHODS: A cost-consequence analysis was developed to quantify the impact of employer exclusion for PPI. The analysis was selected as it displays results in natural units of effect, including the number of men affected and the days and costs of work productivity lost, enabling clinicians and decision makers to select the most relevant components to them. IBM MarketScan Commercial data from 2010-2018 were analyzed to determine the prevalence and comorbid correlations of ED. The American Community Survey and published literature were used to estimate the number of ED men with ESHI affected by benefit exclusion for PPI. The economic impact of work productivity loss due to ED was calculated using National Occupational Employment and Wage Estimates and converted into 2019 US dollars. RESULTS: The prevalence rates of ED among men with ESHI increased from 1.6% in men aged 18-24 years to 24.6% in men aged 55-64 years (Figure). Most ED men were ≥45 years of age (78.5%), had a Charlson Comorbidity Index of 0 (76.1%). Common comorbidities were hyperlipidemia (48.0%) and hypertension (46.4%). An estimated 1.29 million men with ESHI in 2019 were affected by benefit exclusion for PPI. Men with ED had an additional 283 hours/year of work impairment compared to men without ED, resulting in an annual indirect mean cost of $7,270. An average US company with 5,000 employees that excluded PPI from their plan could lose $1.28 million of work productivity due to additional work impairment from ED. CONCLUSIONS: The extent of men with ED affected by benefit exclusion for PPI as well as economic impact of work productivity loss due to this exclusion issue are substantial. Removing benefit exclusion for PPI may improve patient access to effective ED treatment and reduce the burden of ED on both patients and employers . Source of Funding: Boston Scientific © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e474-e474 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Sirikan Rojanasarot More articles by this author Samir Bhattacharyya More articles by this author Arthur L. Burnett More articles by this author Expand All Advertisement Loading ...